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Objectives: Spinal cord stimulation (SCS) is a recognized treatment for chronic pain. This systematic review aims to assess
economic evaluations of SCS for the management of all chronic pain conditions, summarize key findings, and assess the
quality of studies to inform healthcare resource allocation decisions and future research.
Methods: Economic evaluations were identified by searching general medical and economic databases complemented with
screening of reference lists of identified studies. No restrictions on language or treatment comparators were applied. Relevant
data were extracted. The quality of included studies was assessed using the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) checklist.
Results: Fourteen studies met the inclusion criteria and were judged to be of acceptable quality. Economic evaluations
assessed SCS for the management of refractory angina pectoris, failed back surgery syndrome (FBSS), complex regional pain
syndrome (CRPS), diabetic peripheral neuropathy (DPN), and peripheral arterial disease. Model-based studies typically
applied a 2-stage model, i.e. decision tree followed by Markov model. Time horizon varied from 1 year to lifetime. Cost-
effectiveness ranged widely from dominant (SCS cost-saving and more effective) to incremental cost-effectiveness ratio of
.£100,000 per quality-adjusted life-year. Cost-effectiveness appeared to depend on the time horizon, choice of
comparator, and indication. Ten of the studies indicated SCS as cost-saving or cost-effective compared with the alternative
strategies.
Conclusion: The results consistently suggest that SCS is cost-effective when considering a long-term time horizon, particularly
for the management of FBSS and CRPS. Further studies are needed to assess the cost-effectiveness of SCS for ischemic pain
and DPN.
Keywords: chronic pain, full economic evaluations, spinal cord stimulation, systematic review.
VALUE HEALTH. 2020; -(-):-–-Introduction
Chronic pain imposes a significant economic burden. The cost
of back pain alone has been estimated at around one-fifth the total
healthcare expenditure in a country or 1.5% of annual gross do-
mestic product.1 In 2017, the direct medical costs of chronic pain
in the United Kingdom were approximately £580 million calcu-
lated from the total prescription of analgesic medication and pain-
related primary care appointments.2 Nevertheless, the impact on
direct medical costs is relatively small compared with the societalss correspondence to: Rui V. Duarte, Liverpool Reviews and Implementation
Kingdom. Email: rui.duarte@liverpool.ac.uk
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cess article under the CC BY license (http://creativecommons.org/licenses/b
doi.org/10.1016/j.jval.2020.02.005economic burden of chronic pain. Chronic pain causes long-term
disability leading to work absence, with productivity costs hav-
ing a significant impact on economic burden. Indirect costs of back
pain in the United Kingdom are estimated at about £11 billion
using the human capital approach and £5 billion using the friction
cost method.3
Spinal cord stimulation (SCS) is considered for patients with
chronic pain unresponsive to more conservative treatment. SCS is
commonly used for management of neuropathic conditions such
as failed back surgery syndrome (FBSS), complex regional painGroup, University of Liverpool, Whelan Building, Liverpool L69 3GB, England,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
2 VALUE IN HEALTH - 2020syndrome (CRPS), diabetic peripheral neuropathy (DPN), and
ischemic conditions such as peripheral arterial disease (PAD) and
refractory angina pectoris (RAP). SCS has been the subject of
economic evaluations since the 1990s.4 Previous systematic re-
views of economic evaluations of SCS have focused on results of
studies rather than methodologies.5,6 Furthermore, previous re-
views included only economic evaluations of conventional SCS
(Con-SCS). With the introduction of a number of new SCS mo-
dalities including high-frequency SCS (HF-SCS), burst SCS, and
dorsal root ganglion stimulation, the cost-effectiveness of these
alternatives warrants review.
The aims of this systematic review are to assess the current
state of economic evaluations of SCS for all chronic pain condi-
tions, appraise the quality of this literature, and summarize key
findings to support healthcare policy decision making for SCS.Methods
The protocol for this systematic review is registered on the
International Perspectives Register of Systematic Reviews as
CRD42018090412. This review is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA).7
Search Strategy
Electronic databases MEDLINE (including epub ahead of print
and MEDLINE in process), EMBASE, Cochrane Central Register of
Controlled Trials, National Health Service Economic Evaluation
Database, Health Technology Assessment Database, Database of
Abstracts of Reviews of Effects, EconLit, and Cost-Effectiveness
Analysis Registry (CEA Registry) were searched from inception
until July 12, 2019. The MEDLINE search strategy is presented in
Supplementary Material 1 of this article (found at https://doi.org/1
0.1016/j.jval.2020.02.005) and was adapted to enable similar
searches of the other databases. The reference lists of relevant
systematic reviews and eligible studies were hand searched to
identify potentially relevant studies. No language restrictions were
applied.
Study Selection
Identified citations were assessed for inclusion using a 2-stage
process. First, 2 reviewers (S.N., R.V.D.) independently screened
the titles and abstracts to identify potentially relevant articles.
Second, the full-text articles were independently screened by 2
reviewers (S.N., R.V.D.) using the eligibility criteria in Table 1. Any
disagreements were resolved through discussion, and, if neces-
sary, in consultation with a third reviewer (R.S.T.).Table 1. Eligibility criteria.
Inclusion criteria Ex




2. Full economic evaluations (cost-effectiveness, cost-utility, or cost-
benefit) with incremental analysis to a comparator therapy
2.
ou
3. Both costs and clinical or utility outcomes were analyzed or ICER/






DRGS indicates dorsal root ganglion stimulation; ICER, incremental cost-effectivenessData Extraction
A data extraction formwas developed to enable data extraction
relating to bibliographic information and general information,
methodological characteristics (type of economic evaluation,
perspective, time horizon, discount rate, costs and resource use,
model assumptions, primary economic outcomes, and sensitivity
analyses), and main findings. Data were extracted by one reviewer
(S.N.) and checked for accuracy by a second reviewer (R.V.D.). Any
disagreements were resolved through discussion with a third
reviewer if required (R.S.T.).
Quality Assessment
The methodological quality of included evaluations was
assessed using the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) checklist.8 The CHEERS checklist
comprises 24 items and scores each study dichotomously as
having met the criteria in full or not. Quality assessment of
included studies was performed by 1 reviewer (R.V.D.) and
checked by a second reviewer (S.N.). Any disagreements were
resolved through discussion, and, if necessary, in consultation
with a third reviewer (R.S.T.). The results of the quality assessment
based on the CHEERS checklist are provided in Supplementary
Material 2 (found at https://doi.org/10.1016/j.jval.2020.02.005).
Data Synthesis
A narrative synthesis and structured tables were used to pre-
sent information from the economic evaluations identified. The
results are reported in line with good practice recommendations
for narrative summaries of health economic studies as outlined in
the Cochrane Handbook for Systematic Reviews.9
To facilitate the comparison of estimates reported from
different study settings and time frames, results from the eco-
nomic evaluation (incremental cost-effectiveness ratio [ICER], in-
cremental cost-utility ratio [ICUR]) were adjusted and converted
to 2019 UK pounds (£). Conversion of cost estimates was per-
formed using the CCEMG-EPPI-Centre Cost Converter web-based
tool version 1.6, which takes into consideration international ex-
change rates across currencies and years based on gross domestic
product deflator index values and purchasing power parities as
recommended in the Cochrane Handbook.9Results
The searches identified 574 citations with 457 remaining after
the removal of duplicates. After initial screening of titles and ab-
stracts, 18 were considered to be potentially relevant and wereclusion criteria
Economic evaluations related to neurostimulation intervention other
an SCS or DRGS
Partial economic evaluations (cost analysis, cost description, cost
tcome description)
Protocol paper, methodological paper, systematic review or meta-
alysis, reviews or editorial reports of original studies
No comparator group
Insufficient information available (e.g. conference abstracts)
ratio; ICUR, incremental cost-utility ratio; SCS, spinal cord stimulation.
-- 3retrieved to allow assessment of the full text. After full-text re-
view, 14 studies were included.10–23 Four studies did not meet the
eligibility criteria and were excluded.24–27 The PRISMA flow chart
detailing the screening process is shown in Figure 1.
Table 2 presents the characteristics of the included economic
evaluations. Chronic pain conditions assessed included RAP (n =
3), FBSS (n = 8), CRPS (n = 4), DPN (n = 1), and PAD (n = 2). One
study included 3 conditions (FBSS, CRPS, ischemic pain)20 and
another study 4 conditions (FBSS, CRPS, PAD, RAP).18 Six of the
studies assessed the costs of interventions in the United
Kingdom,11,12,15,20,22,23 3 in The Netherlands,14,16,21 2 in the United
States,13,19 2 in Canada,17,18 and 1 in Sweden.10Type of Economic Evaluation and Comparators
Most studies applied CEA or cost-utility analysis. Six studies
conducted trial-based evaluations10,12,14,16,19,21 whereas 6 used
model-based analysis.11,15,18,20,22,23 Seven studies compared SCS
for neuropathic pain versus conventional medical management
(CMM).11,15,17,18,20,22,23 Four used reoperation as the comparator in
patients with FBSS.11,19,20,23 One used observational data and
compared SCS with pre-SCS (ie, usual care and pain clinic) in
FBSS.13 Physical therapy was considered as the comparator for
patients with CRPS14 and best medical treatment (BMT) the
comparator for patients with DPN.21
For ischemic pain, coronary artery bypass graft (CABG),
percutaneous myocardial laser revascularization and percuta-













14 studies included in
evidence synthesisangina pectoris.10,12,20 Two studies assessed CMM or BMT as the
alternative in patients with PAD.16,18
Choice of Model
Six studies were model-based analyses.11,15,18,20,22,23 Most
studies used data from randomized controlled trials (RCTs) as
key input parameters. One study used case-series data and
developed a Markov model.18 All model-based studies evalu-
ating SCS for neuropathic pain applied a 2-stage model (ie,
decision tree followed by a Markov model). One study applied
models for neuropathic pain and ischemic pain separately.20 A
2-stage model was employed for neuropathic pain, and a
mathematical model was applied to ischemic pain.20 A mathe-
matical model was used for ischemic pain owing to lack of
information for input variables.
Economic Perspective
Ten studies adopted a healthcare perspective,11,12,15,17–23 and 3
adopted a societal viewpoint.14,16,21 Results were also presented
from the perspectives of the health insurance council14 and
Department of Labor and Industries.13 The perspective of the eco-
nomic evaluation was not clearly stated in 1 study, although hos-
pital care cost data presented suggest a healthcare perspective.10
Time Horizon and Discount Rates
The time horizons ranged from 1 year to lifetime. One study
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BMT indicates best medical treatment; CABG, coronary artery bypass surgery; CLI, critical limb ischemia; CMM, conventional medical management; CRPS, complex
regional pain syndrome; DPN, diabetic peripheral neuropathy; EE, economic evaluation; FBSS, failed back surgery syndrome; HF-SCS, high-frequency spinal cord
stimulation; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PMR, percutaneous myocardial laser revascularization; PT, physical therapy;
RAP, refractory angina pectoris; RCT, randomized controlled trial; SCS, spinal cord stimulation; TNR, traditional nonrechargeable spinal cord stimulation; TR-SCS,
traditional rechargeable spinal cord stimulation.
*Economic evaluation based on effectiveness data from case series only.
4 VALUE IN HEALTH - 2020Nine studies reported use of discount rates.12–16,18,20,22,23 For 1
study, discount rates were not applicable as the main analysis
considered a time horizon of 12 months.21 The choice of dis-
count rate in 7 of the studies was informed by National Insti-
tute for Health and Care Excellence (NICE) reference case
recommendation at the time of the study (ie, 6% for costs and
1.5% for benefits22 or discount rate of 3.5% for both costs and
benefits).11,12,15,18,20,23 One study discounted both costs and
benefits at 3% as recommended by the US Panel on Cost-
Effectiveness in Health and Medicine.14 One study discountedcosts at 3% without discounting benefits.13 Four studies did not
report discounting.10,16,17,19
Reporting of Costs
Table 3 shows the costs included in each of the economic
evaluations assessing SCS. Incremental costs ranged from cost-
saving to £24 892. Included costs can be grouped into 3 main
categories: direct medical, nondirect medical, and indirect. All
the costs evaluated depended on the study perspective. Studies
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£12 813 827 (£11 787 068)
CMM versus TR-SCS
£7 430 496 (£6 835 098)
CMM versus HF-SCS
£6 318 134 (£5 811 868)
Reoperation as comparator
Reoperation versus TNR-SCS
£11 277 226 (£10 373 593)
Reoperation versus TR-SCS
£5 711 006 (£5 253 389)
Reoperation versus HF-SCS
£4 598 643 (£4 230 158)
TNR-SCS as comparator
TNR-SCS versus TR-SCS
–£5 383 331 (–£4 951 970)
TNR-SCS versus HF-SCS
–£6 495 694 (–£5 975 201)
TR-SCS as comparator
TR-SCS versus TNR-SCS
–£5 566 220 (–£5 120 204)
TR-SCS versus HF-SCS





















































































(95% CI: £1966 to £8613;
P,.01)
0.12 (95% CI: –0.04 to
0.30; P = .96)





















SCS versus usual care
£24 892 ($29 358)
(95% CI: $16 070
to $43 790)
SCS versus pain clinic
£17 020 ($20 074)
(95% CI: $3840
to $35 990)
SCS versus usual care
10% in SCS and 10%
in UC groups on
achieving primary outcome
SCS versus pain clinic
10% in SCS and 3% in
PC groups on achieving
primary outcome
SCS versus usual care
£283 788 ($334 704)
(95% CI: $142 203 to
$489 243)
SCS versus pain clinic
£111 196 ($131 146)
(95% CI: SCS dominates
to $271 075)
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P = .09)
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Kumar et al17 2-y base case
£3220 (V3002)
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£49 151 (V45 819)
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BMT indicates best medical treatment; BNF, British National Formulary; CABG, coronary artery bypass surgery; CHD, coronary heart disease; CI, confidence interval; CLI,
critical limb ischemia; CMM, conventional medical management; CRPS, complex regional pain syndrome; DPN, diabetic peripheral neuropathy; FBSS, failed back surgery
syndrome; GBP, British pound sterling; GP, general practitioner; HRG, Health Resource Group; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility
ratio; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PAD, peripheral arterial disease; QALY, quality-adjusted life-year; RAP,
refractory angina pectoris; SCS, spinal cord stimulation; TNR-SCS, traditional nonrechargeable spinal cord stimulation; TR-SCS, traditional rechargeable spinal cord
stimulation; UC, usual care; WTP, willingness to pay.
*Costs reported in 2019 GBP. The values in parentheses represent the costs originally reported.
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-- 7inconsistently evaluated the cost of the SCS intervention
because various types of costs were applied. Direct medical
costs were evaluated in all studies and were the key inputs for
the cost analysis. Direct medical costs can be grouped into 3
types depending on the SCS treatment period: initial costs,
that is, (1) preimplantation costs (or testing and screening
costs), (2) surgery or implantation costs (mainly covered in
device and surgery hospitalization costs), and (3) post-
implantation costs (costs for device maintenance, complica-
tions, reimplantation, or removal). For the initial SCS costs, 1
study applied only implantation or procedure costs,10 whereas
2 studies did not clearly state the type of medical costs
assessed.12,19 Most studies considered post-implantation costs,
which varied between studies although mostly included costs
of complications, reimplantation, or device removal. One study
applied annual SCS maintenance costs separated from reim-
plantation costs.22
Costing of resource use datawas derived from different sources.
Twelve studies described the approach used to estimate unit costs
and cost calculations.12–23 One study did not report the method
used to calculate the unit costs.11 One study did not state sources of
cost or unit cost calculation.10 Three studies used national data to
calculate costs.12,20,23 Costs were derived from previous cost-
analysis and economic evaluations in 3 studies.11,15,22 Three
studies applied SCS device costs from manufacturers.15,16,23
Methods to assess productivity loss included work time-loss
compensation payments to workers13 and the friction method.21
Reporting of Effectiveness
All studies provided the choice of outcome measurement.
Eleven studies reported the measurement of effectiveness and
valuation of preference-based outcomes.11,12,14,15,18–23 One study
did not report the data source of effect.10 Most of the effec-
tiveness data were collected from RCT and observational data.
One study estimated effectiveness data based on a literature
review.20 Pain outcome measurement varied from the propor-
tion of patients achieving 50% pain relief, pain exacerbation, and
patient satisfaction. Two studies analyzed the final outcome as
mortality.10,16 The health-related quality of life measured by
using a generic measurement with multi-attributes such as the
EQ-5D, was reported in 10 studies.11,12,14,15,18–23 One short-term
study estimated missing EQ-5D data by interpolation between
adjacent visits or valuing from the last visit and extrapolating to
the time horizon.12
Economic Evaluation Results
Economic evaluation results are illustrated in Table 3. Eleven
studies reported ICERs/ICURs as the final economic evaluation
outcome. Three studies performed full economic evaluations by
comparing costs and outcomes but did not calculate ICER/ICUR as
SCS was found to be dominant or dominated.10,16,17 Seven of the
studies stated the willingness-to-pay threshold based on study
setting and used the NICE threshold, which ranges from £20 000
to £30 000 per quality-adjusted life-year (QALY)
gained.11,12,15,18,20,21,23 One Canadian study used both NICE and
Canadian ($50 000 per QALY) thresholds.18
The ICERs/ICURs varied widely from cost-saving to more than
£100 000 per QALY depending on the indication, time horizon,
and comparator. SCS was estimated to be cost-saving and cost-
effective over long-time periods, from 15 years to lifetime, for
most chronic pain conditions considered. The results of studies
with a long time horizon are shown in Figure 2A. Eight studies
evaluated SCS for FBSS pain.11,13,17–20,22,23 The ICER/ICUR in FBSS
ranged from cost-saving to £283 788 per additional QALY gained.The overall trend was toward SCS being cost-effective compared
with CMM alone, especially in longer time horizons. SCS therapy
was cost-saving compared with reoperation when used for FBSS.19
In contrast, 1 observational study of SCS for FBSS patients
compared with usual care and pain clinic found that SCS was not
cost-effective, reporting an ICER of £283 788 per additional QALY
gained (Figure 2B).13 Four studies considered SCS as highly cost-
effective compared with reoperation regardless of time horizon.
Nevertheless, SCS was not cost-effective in the short-term (ie, 2-
year time horizon) when compared with CMM,22 pain clinic,13
or usual care.13
Four studies assessed the cost-effectiveness of SCS for patients
with CRPS. One short horizon study evaluating SCS for CRPS
considered SCS cost-effective per the NICE threshold.14 One study
found SCS to be cost saving compared with physiotherapy alone
considering a lifetime time horizon and also cost-effective in the
short-term from the first year of SCS therapy.14 Two studies of SCS
versus CMM over a 15-year time horizon reported different re-
sults, with ICURs of £428515 and £31 04620 per additional QALY.
One study assessed SCS versus BMT in patients with DPN and
found that SCS was not cost effective over 1 year.21
Three studies evaluated SCS for RAP with different compara-
tors and time horizons. SCS for persistent pain after CABG was
cost-effective over a 20-year follow-up when compared with
CMM, with an ICER/ICUR of £6345 per QALY.18 On the other hand,
SCS was not cost-effective compared with percutaneous myocar-
dial laser revascularization at 2-year follow-up.12 One study of SCS
versus CABG reported lower costs and higher effectiveness for SCS
(ie, SCS dominant).10
One study showed SCS to be cost-effective for PAD over 20
years, with an ICER/ICUR of £6345 per additional QALY gained.18
Nevertheless, another study with a 2-year analysis period
concluded that SCS was not cost-effective for the management of
critical limb ischemia.16
Sensitivity Analysis
To assess the generalizability and uncertainty of the results,
deterministic and probabilistic sensitivity analyses were per-
formed in most studies. One-way sensitivity analysis and/or
probabilistic sensitivity analysis were reported in 10
studies.11–15,18,20–23 Two studies used nonparametric boot-
strapping and multiway analysis.19,22 Supplementary Material 3
(found at https://doi.org/10.1016/j.jval.2020.02.005) presents the
types of input parameters affecting the ICER/ICUR and the prob-
ability of SCS being cost-effective. For the studies that conducted
sensitivity analysis, all of the input parameters were analyzed with
discounted costs and outcomes. The ICERs/ICURs were found to be
sensitive to the change in SCS equipment costs, costs of pain
medication, probability of optimal and suboptimal pain relief,
costs, and QALY gain from optimal and suboptimal health states
with SCS.
The probability of SCS being cost-effective, at the appropriate
range of the cost-effectiveness willingness-to-pay threshold, was
more than 70% in 5 studies.15,18–20,23 One study found that the
probability of SCS being cost-effective was below 20%.13 One study
performed expected value of perfect information; the expected
value of perfect information result for SCS estimate per patient
was relatively low compared with the total cost per patient.18
Type of SCS Devices and Battery Longevity
All of the studies considered traditional nonrechargeable SCS
(TNR-SCS) devices. Two studies extended the analysis to tradi-
tional rechargeable SCS (TR-SCS) and compared it with TNR-SCS in
patients with FBSS and CRPS.15,23 The studies assumed a fixed
Figure 2. Incremental cost-effectiveness ratio/incremental cost-utility ratio when considering a long-term (A) or short-term (B) time
horizon.
*Spinal cord stimulation dominant (ie, less costly and more effective).
8 VALUE IN HEALTH - 2020battery life of 9 years for TR-SCS and varied the battery longevity
up to 16 years for TNR-SCS. When all other parameters were fixed,
TR-SCS was more cost-effective than TNR-SCS, for which the ex-
pected longevity of TNR-SCS was less than 4 years. One study
assessed HF-SCS in patients with FBSS compared with CMM,
reoperation, TR-SCS, and TNR-SCS.11 The results showed that HF-
SCS was cost-effective with ICERs of £3153 and £2666 per QALY
gained versus CMM and reoperation, respectively. TR-SCS was
more cost-effective than TNR-SCS; however, HF-SCS dominated
both TNR-SCS and TR-SCS.11Discussion
The focus of this systematic review was on full economic
evaluations. Fourteen studies met the eligibility criteria. SCS was
mostly considered to be cost-effective; however, this depended on
the chronic pain condition, comparator treatments, time horizon,
and willingness-to-pay threshold.
Previous systematic reviews of cost-effectiveness of SCS found
a limited number of economic evaluations. A systematic review of
SCS therapy in patients with FBSS included 3 studies, of which 2studies were full economic evaluations and another study was a
cost-consequences analysis.6 A systematic review of SCS therapy
for CRPS found only 1 well-conducted economic evaluation.5 Be-
sides the limited number of studies identified, both of these re-
views did not include detailed evaluation of the methods
employed, were mostly focused on the results, and did not
perform adjustment of costs from different prices, years, and
settings.
Although this systematic review shows that the average costs
of SCS tend to be higher than the alternative options, especially at
the initial stages of the treatment, the improvement in health-
related quality of life compensates this in the long-term. Hence,
the time horizon to evaluate SCS interventions should be long
enough to capture the differences between treatment and
comparator. The results of trial-based studies were limited to a
short period of time and may neglect relevant events that can
occur later and have a potential impact on costs and health out-
comes. Nevertheless, the analytical models were limited by a lack
of some long-term data or missing follow-up costs. Therefore,
even though a lifetime horizon is preferable, the assumptions of
the model when extrapolating into the long-term should be made
explicit to increase model transparency and strengthen the cost-
-- 9effectiveness evidence. One study, which assessed SCS in patients
with FBSS, used a conservative value for pain relief over time and
assumed a complication rate of 0% with CMM. The 1-way sensi-
tivity analysis found that the results were sensitive to SCS annual
complication rate and may underestimate the cost-effectiveness of
SCS compared with CMM.22
Preimplantation costs such as screening and testing for
response should be included in the analysis. All studies included
SCS-related complication costs after surgery, for instance, costs for
explantation of the device, revision costs, and follow-up costs.
Economic evaluations with a time horizon longer than 1 year
should discount future costs and benefits. Although the discount
rates for costs and benefits vary between and even within coun-
tries (eg, NICE and HM Treasury in the United Kingdom), an
appropriate discount rate should be applied in the base case, with
sensitivity analyses carried out to examine the impact of other
relevant discount rates.
The rationale for choosing the comparator should be clearly
presented. Alternative options for the management of FBSS
included CMM or reoperation; however, from an evidence-based
approach, medication management and reoperation provide
weak evidence of clinical improvement in patients with FBSS.6,31
The study comparator should be based on current practice or
clinical guidelines with the adequacy of the comparator clearly
presented. Another limitation observed from included studies is
the unclear characterization of uncertainty, particularly in trial-
based economic evaluations. The statistical uncertainty of CEA
can be analyzed using confidence intervals or Bayesian credibility




The use of SCS for the management of patients with FBSS can
be considered as cost-effective, particularly when considering
long-term time horizons. SCS intervention versus CMM alone
was found to be cost-effective from the first 2 years and cost-
saving over a lifetime time horizon.11,17,18,20,22,23 SCS was also
estimated as cost-effective or cost-saving when compared with
reoperation.11,19,20,23
Regarding these 2 strategies (ie, comparison of SCS with
CMM or reoperation), CMM data were collected from an inter-
national RCT,32 which can be considered as having high internal
validity and well-controlled, making CEA more robust, whereas
the data from reoperation were based on case series and a
small RCT.33 Importantly, in the model-based analysis of SCS,
data on the complications of CMM and reoperation were un-
available, and assumed “conservative” values were used in the
models. These conservative assumptions might lead to unpre-
dictably biased cost-effectiveness results. Although CMM and
reoperation are recommended as a standard treatment for FBSS,
recent evidence suggests that medication management and
reoperation yielded inferior efficacy when compared with other
treatment options such as epidural injection or adhesiolysis.31
Therefore, further analysis of SCS compared with these alter-
natives would be welcome as well as utility values associated
with complications resulting from pain management with CMM
and reoperation.
CRPS
Because there is no curative treatment available for CRPS,
current practice is to combine medication management and
physical and occupational therapy. SCS treatment has been
shown to reduce pain significantly in patients experiencingCRPS.34 In this systematic review, it was observed that SCS for
CRPS is cost-effective. Nevertheless, similar to economic evalu-
ations of SCS for patients with FBSS, there was no direct esti-
mation of utility values associated with complications from
CMM or alternative treatment strategies. One study compared
SCS with PT and demonstrated that SCS was cost-effective from
year 1 and became cost-saving over the lifetime.14 Nevertheless,
this study was based on data from a clinical trial, and unit
prices were calculated via microcosting from the Dutch popu-
lation. Hence, the applicability of the results to the UK popu-
lation should be considered.
Diabetic Peripheral Neuropathy
One published study assessed the cost-effectiveness of SCS in
patients with painful DPN comparing SCS with BMT over 1 year.21
Because of the high initial treatment costs on the SCS arm, SCS
was not considered to be cost-effective from either a healthcare or
societal perspective, even though SCS yielded more QALYs than
BMT did. Nevertheless, it was suggested that SCS is likely to
become more cost-effective in the long-term considering the
depreciation of SCS material and extrapolating the data for up to 4
years.
Ischemic Pain
The clinical evidence available on the use of SCS for the man-
agement of ischemic pain is limited, with SCS used less frequently
in this patient group. The results of economic evaluations of SCS
for ischemic conditions range from cost-saving to ICERs of £230
000 per additional QALY gained. One study has suggested that the
ICER could range from £18 000 to £230 000 per QALY gained
considering the clinician’s experience.12
Strengths and Limitations of the Review
The review methods, including study identification, selection,
quality assessment, and data extraction, were carried out in line
with PRISMA recommendations.7 No constraints were set on the
type of SCS device studied or population of interest. All types of
full economic evaluations35 were considered relevant, including
both trial- and model-based economic evaluations.
Our review can be considered limited by focusing on full eco-
nomic evaluations, which means that partial economic evalua-
tions (such as cost analyses) were not included. Nevertheless,
although such partial evaluation studies can offer detailed infor-
mation into the costs associated with a treatment, they do not
provide information to aide resource allocation decisions and
therefore are less valuable for decision making.35,36
Policy Implications and Future Research
The findings from this review have important implications for
healthcare policy makers. This systematic review found that SCS is
considered economically favorable in neuropathic pain of FBSS
and CRPS. The review highlights the benefit from the reduction in
healthcare expenditure in long-term treatment. Nevertheless,
further evidence is required to definitively determine the cost-
effectiveness of SCS for ischemic pain. This review also reports
the information available on the cost-effectiveness of the several
types of SCS device systems, with suggestions that HF-SCS is more
cost-effective than conventional TR-SCS and TNR-SCS. The results
of HF-SCS should be interpreted with caution as current evidence
is limited to 1 economic evaluation making several assumptions
(eg, complication rates assumed to be the same for HF-SCS and
comparators), the effectiveness data for HF-SCS derived from 1
case series with a 6-month follow-up (validated with data from a
case series with 24-month follow-up), and with no utility data (ie,
10 VALUE IN HEALTH - 2020utility values assumed to be the same for HF-SCS as for conven-
tional SCS). There is a lack of evidence for the cost-effectiveness of
dorsal root ganglion stimulation.
Chronic pain may be a lifelong condition; therefore, it is
important to assess long-term clinical outcomes and the quality of
life of patients with SCS. Most of the studies applied short-term
data and extrapolated to lifetime analysis because of the un-
availability of long-term data. SCS needs to be compared with
treatment options based on current recommendations and clinical
guidelines. Moreover, more research is needed on the use of SCS
for other chronic pain conditions such as phantom limb pain or
peripheral neuralgia.
Conclusion
The results of this review show that SCS is a cost-effective
therapy when considering long-term treatment for patients with
neuropathic pain (ie, FBSS and CRPS). The results from economic
evaluations assessing SCS for patients with ischemic pain require
further evaluation because of the lack of clinical data. HF-SCS may
be more cost-effective than conventional SCS. Nevertheless, these
results are limited to the indications of FBSS and CRPS, with
additional research required for other chronic pain conditions.
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